Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -57.69% | -29.46% | -1.54% | 3.37% | 47.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -57.69% | -29.46% | -1.54% | 3.37% | 47.01% |
| Cost of Revenue | -60.36% | -43.35% | -8.88% | 2.59% | 23.66% |
| Gross Profit | 60.45% | 43.80% | 9.12% | -2.57% | -23.01% |
| SG&A Expenses | -29.58% | -19.25% | -2.92% | 21.05% | 21.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.18% | -36.87% | -7.18% | 7.16% | 23.06% |
| Operating Income | 52.05% | 37.04% | 7.32% | -7.24% | -22.57% |
| Income Before Tax | 61.69% | -15.52% | -49.14% | -58.11% | -66.57% |
| Income Tax Expenses | -67.80% | -50.85% | -33.90% | -9.09% | 51.28% |
| Earnings from Continuing Operations | 61.70% | -15.47% | -49.07% | -58.05% | -66.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.70% | -15.47% | -49.07% | -58.05% | -66.56% |
| EBIT | 52.05% | 37.04% | 7.32% | -7.24% | -22.57% |
| EBITDA | 52.37% | 37.32% | 7.24% | -7.80% | -23.73% |
| EPS Basic | 64.79% | 6.28% | -3.52% | 4.63% | 2.15% |
| Normalized Basic EPS | 56.84% | 47.84% | 33.98% | 34.09% | 26.67% |
| EPS Diluted | 64.79% | 6.28% | -3.52% | 4.63% | 2.15% |
| Normalized Diluted EPS | 56.84% | 47.84% | 33.98% | 34.09% | 26.67% |
| Average Basic Shares Outstanding | 11.50% | 21.88% | 38.57% | 62.08% | 64.33% |
| Average Diluted Shares Outstanding | 11.50% | 21.88% | 38.57% | 62.08% | 64.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |